Objective To develop a Medical Adhesive Related Skin Injury Risk Assessment Scale in Cancer Patients,and to test its reliability and validity. Methods The scale was compiled on the basis of literature analysis,group discussion and 2 rounds of expert consultations. Using the convenient sampling method,a total of 306 patients in departments of oncology of 3 tertiary A hospitals in Henan Province from March to July 2021 were selected for questionnaire survey to test the reliability and validity of the scale. Results The scale includes 7 dimensions,including patient factors,disease history,laboratory examination,skin status,adhesive properties,treatment cycle and catheter maintenance factors,with a total of 25 items. 7 common factors were extracted by exploratory factor analysis,and the cumulative variance contribution rate was 77.52%;the load values of each item in its common factor were 0.63~0.96;the content validity index at the scale level was 0.91,and the content validity index at the item level was 0.81~1.00. The area under the operating characteristic curve of the scale for predicting the risk of medical adhesive related skin injury in cancer patients was 0.87（P<0.001,95%CI ：0.72~0.83）;the cut-off value was 27.50 points. The Cronbach’s α coefficient was 0.81 and the half reliability was 0.55. Conclusion The risk assessment scale constructed by this study has good reliability and validity,and it can be used to assess the risk of medical adhesive related skin injury in cancer patients.

Objective To identify the development trajectory of early fatigue and its influencing factors in patients with malignant melanoma treated with PD-1 inhibitor. Methods Using the longitudinal data of patients with malignant melanoma after operation,the Group - Based Trajectory Model was used to identify the development trajectory of early fatigue symptoms in 106 patients with PD-1 inhibitors single drug adjuvant treatment,and the multiple logistic regression was used to analyze the influencing factors of the development trajectory of early fatigue symptoms. Results 2 early fatigue development trajectories of “fatigue relieving group” and “fatigue increasing group” were identified. Univariate analysis showed that there were significant differences in tumor location（ χ²=9.046,P=0.011）,self-care ability（ χ²=20.407,P<0.001）,remission after rest（ χ²=54.804,P<0.001） and the number of other irAEs（ χ²=26.312,P<0.001） among the subgroups. Multiple logistic regression analysis showed that early fatigue symptoms relieved after rest （RR=0.026,95%CI[0.004,0.179]） and accompanied by 0 other irAEs（RR=0.255,95%CI[0.181,0.361]） were less likely to be classified as type 2 “increased fatigue group”. Conclusion The development of early fatigue in patients with malignant melanoma treated with PD-1 inhibitor as a single drug adjuvant showed different changing trajectories. Nurses should pay attention to the evaluation and intervention of early fatigue symptoms in patients with non relief of fatigue symptoms after rest and other irAEs.